MESO Mesoblast Ltd

Price (delayed)

$15.31

Market cap

$1.97B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.74

Enterprise value

$1.98B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32

mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells ...

Highlights
The quick ratio has soared by 141% YoY
Mesoblast's equity has increased by 25% YoY
The gross margin fell by 20% YoY
The debt is up by 7% year-on-year

Key stats

What are the main financial stats of MESO

MESO stock price

How has the Mesoblast stock price performed over time
Intraday
-4.79%
1 week
-11.61%
1 month
-1.54%
1 year
-9.84%
YTD
-15.13%
QTD
13.16%

Financial performance

How have Mesoblast's revenue and profit performed over time
Revenue
$65.38M
Gross profit
$52.65M
Operating income
-$66.13M
Net income
-$94.37M
Gross margin
80.5%
Net margin
-144.3%
The net margin has surged by 92% year-on-year
The operating margin has surged by 89% year-on-year
MESO's operating income is down by 31% year-on-year
The gross margin fell by 20% YoY

Price vs fundamentals

How does MESO's price correlate with its fundamentals

Growth

What is Mesoblast's growth rate over time

Valuation

What is Mesoblast stock price valuation
P/E
N/A
P/B
3.41
P/S
29.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.25
The EPS has increased by 21% YoY
Mesoblast's equity has increased by 25% YoY
The stock's P/B is 10% above its last 4 quarters average of 3.1
The stock's price to sales (P/S) is 81% less than its last 4 quarters average of 156.0

Efficiency

How efficient is Mesoblast business performance
The ROS has soared by 93% YoY
The ROA has grown by 16% YoY
MESO's ROE is up by 15% year-on-year
MESO's ROIC is up by 9% YoY

Dividends

What is MESO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MESO.

Financial health

How did Mesoblast financials performed over time
The quick ratio has soared by 141% YoY
MESO's current ratio has surged by 65% year-on-year
The debt is 76% smaller than the equity
Mesoblast's equity has increased by 25% YoY
Mesoblast's debt to equity has decreased by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.